Abstract
Critical interpretations and analysis in diagnostic proteomics have accelerated with relevance to various biomarker tests that
involve proteomics, lipidomics and genomics that assist with drug therapy to prevent programmed cell death with relevance to severity
of global chronic disease progression. Reversal of global non-alcoholic fatty liver disease (NAFLD) is essential with analysis of
various plasma components that may override diagnostic proteomics with relevance to defective nuclear-mitochondria interactions
and therapeutic drug efficacy. Therapeutic drug effectiveness and the measurement of multiple proteins/peptides for patient care
requirements now require anti-aging gene Sirtuin 1 (Sirt 1) analysis that is related to toxic amyloid beta:protein interactions and
relevant to therapeutic drug metabolism in diabetes and neurodegenerative diseases.
involve proteomics, lipidomics and genomics that assist with drug therapy to prevent programmed cell death with relevance to severity
of global chronic disease progression. Reversal of global non-alcoholic fatty liver disease (NAFLD) is essential with analysis of
various plasma components that may override diagnostic proteomics with relevance to defective nuclear-mitochondria interactions
and therapeutic drug efficacy. Therapeutic drug effectiveness and the measurement of multiple proteins/peptides for patient care
requirements now require anti-aging gene Sirtuin 1 (Sirt 1) analysis that is related to toxic amyloid beta:protein interactions and
relevant to therapeutic drug metabolism in diabetes and neurodegenerative diseases.
| Original language | English |
|---|---|
| Pages | 209-2015 |
| Number of pages | 7 |
| Volume | 6.4 |
| Specialist publication | EC Pharmacology and Toxicology |
| Publication status | Published - 6 Mar 2018 |
